CURRENT ISSUE [Volume 4, 2019]
-
Autism Spectrum Disorder: Medications overview2019, Volume 4, Issue 1, January-April [Download Full PDF]
- FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome
2019, Volume 4, Issue 1, January-April [Download Full PDF]
- Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review
2019, Volume 4, Issue 1, January-April [Download Full PDF]
- Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura
2019, Volume 4, Issue 1, January-April [Download Full PDF]
- Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review
2019, Volume 4, Issue 1, January-April [Download Full PDF]
- Siponimod: A new approved oral drug to treat multiple sclerosis
2019, Volume 4, Issue 2, May-August [Download Full PDF]
- Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease
2019, Volume 4, Issue 2, May-August [Download Full PDF]
- FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies?
2019, Volume 4, Issue 3, September-December [Download Full PDF]
- Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health
2019, Volume 4, Issue 3, September-December [Download Full PDF]